Armata Pharmaceuticals, Inc.
US ˙ NYSEAM ˙ US04216R1023

Introduction

This page provides a comprehensive analysis of the known insider trading history of Igor Bilinsky. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Igor Bilinsky has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:IOVA / Iovance Biotherapeutics, Inc. Chief Operating Officer 99,689
US:ONCT / Oncternal Therapeutics, Inc. Chief Business Officer 130,000
US:APHB / Ampliphi Biosciences Corp. Chief Operating Officer 87,161
GM, Immuno-Oncology/SVP Sp Ops 6,960
US:VICL / Vical Inc. Sr VP, Corporate Development 193,798
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Igor Bilinsky. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ARMP / Armata Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ARMP / Armata Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ARMP / Armata Pharmaceuticals, Inc. Insider Trades
Insider Sales ARMP / Armata Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ARMP / Armata Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ARMP / Armata Pharmaceuticals, Inc. Insider Trades
Insider Purchases IOVA / Iovance Biotherapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ARMP / Armata Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IOVA / Iovance Biotherapeutics, Inc. Insider Trades
Insider Sales IOVA / Iovance Biotherapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ARMP / Armata Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IOVA / Iovance Biotherapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Igor Bilinsky as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-09-04 2025-09-02 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -6,250 99,689 -5.90 2.19 -13,688 218,319
2025-09-04 2025-09-02 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 12,306 105,939 13.14
2025-06-04 2025-06-02 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -6,250 93,633 -6.26 1.76 -11,000 164,794
2025-06-04 2025-06-02 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 12,305 99,883 14.05
2025-03-05 2025-03-03 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -33,302 87,578 -27.55 4.04 -134,540 353,815
2025-03-05 2025-03-03 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 62,106 120,880 105.67
2025-01-16 2025-01-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -1,578 58,774 -2.61 5.89 -9,294 346,179
2025-01-16 2025-01-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 2,813 60,352 4.89
2024-12-04 2024-12-02 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -1,784 57,539 -3.01 9.07 -16,181 521,879
2024-12-04 2024-12-02 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 3,516 59,323 6.30
2024-10-16 2024-10-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -1,428 55,807 -2.49 9.77 -13,952 545,234
2024-10-16 2024-10-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 2,813 57,235 5.17
2024-09-05 2024-09-03 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -11,891 54,422 -17.93 10.85 -129,017 590,479
2024-09-05 2024-09-03 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 23,438 66,313 54.67
2024-09-05 2024-09-03 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -1,784 42,875 -3.99 10.85 -19,356 465,194
2024-09-05 2024-09-03 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 3,516 44,659 8.55
2024-07-17 2024-07-15 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -1,428 41,143 -3.35 8.68 -12,395 357,121
2024-07-17 2024-07-15 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 2,813 42,571 7.08
2024-06-05 2024-06-03 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -1,784 39,758 -4.29 8.37 -14,932 332,774
2024-06-05 2024-06-03 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 3,516 41,542 9.25
2024-04-17 2024-04-15 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -1,427 38,026 -3.62 11.89 -16,967 452,129
2024-04-17 2024-04-15 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 2,812 39,453 7.67
2024-03-06 2024-03-04 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -7,287 36,641 -16.59 16.96 -123,588 621,431
2024-03-06 2024-03-04 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 14,061 43,928 47.08
2024-01-18 2024-01-16 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -1,577 29,867 -5.02 8.37 -13,199 249,987
2024-01-18 2024-01-16 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 2,813 31,444 9.83
2023-10-18 2023-10-16 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -1,395 28,631 -4.65 3.57 -4,980 102,213
2023-10-18 2023-10-16 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 2,813 30,026 10.34
2023-07-17 2023-07-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -1,395 27,213 -4.88 7.76 -10,825 211,173
2023-07-17 2023-07-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 2,813 28,608 10.91
2023-04-18 2023-04-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -1,395 25,795 -5.13 5.64 -7,868 145,484
2023-04-18 2023-04-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 2,812 27,190 11.53
2023-01-19 2023-01-17 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -4,671 24,378 -16.08 6.43 -30,035 156,751
2023-01-19 2023-01-17 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 11,248 29,049 63.19
2023-01-05 2023-01-03 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -10,553 17,801 -37.22 6.11 -64,479 108,764
2023-01-05 2023-01-03 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 18,850 28,354 198.34
2022-06-16 2022-06-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
F - Taxes -9,346 9,504 -49.58 7.73 -72,245 73,466
2022-06-16 2022-06-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Common Stock
M - Exercise 18,850 18,850
2022-01-19 2022-01-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 67,500 67,500
2022-01-19 2022-01-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Restricted Stock Units
A - Award 33,750 33,750
2021-06-16 2021-06-14 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Restricted Stock Units
A - Award 37,700 37,700
2021-03-16 2021-03-15 4 IOVA IOVANCE BIOTHERAPEUTICS, INC.
Stock Option (right to buy)
A - Award 150,000 150,000
2021-02-16 2021-02-11 4 ONCT Oncternal Therapeutics, Inc.
Stock Option
A - Award 130,000 130,000
2020-07-31 2019-09-09 4/A ONCT Oncternal Therapeutics, Inc.
Stock Option
A - Award 150,000 150,000
2020-07-31 2020-03-17 4/A ONCT Oncternal Therapeutics, Inc.
Stock Option
A - Award 12,690 12,690
2020-03-18 2020-03-17 4 ONCT Oncternal Therapeutics, Inc.
Stock Option
A - Award -12,690 12,690 -50.00
2019-09-09 2019-09-09 4 ONCT Oncternal Therapeutics, Inc.
Stock Option
A - Award -150,000 150,000 -50.00
2017-06-01 2017-05-30 4 APHB AmpliPhi Biosciences Corp
Stock Option (Right to Buy)
A - Award 87,161 87,161
2017-04-04 2017-04-01 4 APHB AmpliPhi Biosciences Corp
Stock Option (Right to Buy)
A - Award 176,411 176,411
2017-01-31 2017-01-30 4 APHB AmpliPhi Biosciences Corp
Stock Option (Right to Buy)
A - Award 247,322 247,322
2017-01-31 3 APHB AmpliPhi Biosciences Corp
Common Stock
0
2016-01-11 2016-01-07 4 RXDX Ignyta, Inc.
Common Stock
A - Award 6,960 6,960
2015-09-17 2015-09-17 4 RXDX Ignyta, Inc.
Stock Option (Right to Buy)
A - Award 200,000 200,000
2015-07-15 2015-07-13 4 VICL VICAL INC
Common Stock $.01 par value
S - Sale X -1,258 193,798 -0.64 0.70 -879 135,368
2015-04-15 2015-04-13 4 VICL VICAL INC
Common Stock $.01 par value
S - Sale X -1,257 195,056 -0.64 0.93 -1,173 181,987
2015-01-21 2015-01-19 4 VICL VICAL INC
Nonstatutory Stock Option (right to buy)
A - Award 61,249 140,000 77.78
2015-01-21 2015-01-19 4 VICL VICAL INC
Employee Stock Option (right to buy)
A - Award 78,751 78,751
2015-01-21 2015-01-19 4 VICL VICAL INC
Common Stock $.01 par value
A - Award 70,000 196,313 55.42 0.01 700 1,963
2015-01-14 2015-01-12 4 VICL VICAL INC
Common Stock $.01 par value
S - Sale X -1,335 126,313 -1.05 1.16 -1,544 146,056
2014-10-14 2014-10-13 4 VICL VICAL INC
Common Stock $.01 par value
S - Sale X -1,335 127,648 -1.04 1.08 -1,446 138,217
2014-08-27 2014-08-26 4 VICL VICAL INC
Common Stock $.01 par value
S - Sale X -12,500 128,983 -8.83 1.25 -15,671 161,706
2014-07-15 2014-07-11 4 VICL VICAL INC
Common Stock $.01 par value
S - Sale X -1,335 141,483 -0.93 1.16 -1,554 164,644
2014-04-14 2014-04-11 4 VICL VICAL INC
Common Stock $.01 par value
S - Sale X -1,150 142,818 -0.80 1.21 -1,387 172,281
2014-01-15 2014-01-10 4/A VICL VICAL INC
Common Stock $.01 par value
A - Award 90,000 143,968 166.77 0.01 900 1,440
2014-01-14 2014-01-13 4 VICL VICAL INC
Common Stock $.01 par value
F - Taxes -305 143,968 -0.21 1.34 -409 192,917
2014-01-14 2014-01-11 4 VICL VICAL INC
Common Stock $.01 par value
F - Taxes -1,419 144,273 -0.97 1.42 -2,015 204,868
2014-01-14 2014-01-10 4 VICL VICAL INC
Nonstatutory Stock Option (right to buy)
A - Award 135,000 540,826 33.27
2014-01-14 2014-01-10 4 VICL VICAL INC
Common Stock $.01 par value
P - Purchase 90,000 145,692 161.60 1.42 127,800 206,883
2014-01-08 2014-01-07 4 VICL VICAL INC
Common Stock $.01 par value
F - Taxes -54 55,692 -0.10 1.31 -71 72,957
2013-12-20 3 VICL VICAL INC
Common Stock
55,746
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)